Cellectis SA (CLLS)
2.99
0.00 (0.00%)
USD |
NASDAQ |
May 03, 16:00
3.05
+0.06
(+2.01%)
After-Hours: 20:00
Cellectis Gross Profit Margin (Quarterly): 40.99% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 40.99% |
| September 30, 2023 | -16.77% |
| June 30, 2023 | 69.27% |
| March 31, 2023 | -140.3% |
| December 31, 2022 | 95.69% |
| September 30, 2022 | -108.5% |
| June 30, 2022 | 74.81% |
| March 31, 2022 | 76.89% |
| December 31, 2021 | -84.97% |
| September 30, 2021 | -10.87% |
| June 30, 2021 | -5.18% |
| March 31, 2021 | 68.18% |
| December 31, 2020 | -80.49% |
| September 30, 2020 | -26.56% |
| June 30, 2020 | -100.9% |
| March 31, 2020 | 90.82% |
| December 31, 2019 | -28.42% |
| September 30, 2019 | 49.86% |
| Date | Value |
|---|---|
| June 30, 2019 | 29.25% |
| March 31, 2019 | 43.34% |
| December 31, 2018 | 16.80% |
| September 30, 2018 | 4.09% |
| June 30, 2018 | 88.93% |
| March 31, 2018 | 90.41% |
| December 31, 2017 | 84.89% |
| September 30, 2017 | 90.71% |
| June 30, 2017 | 91.33% |
| March 31, 2017 | 90.93% |
| December 31, 2016 | 92.33% |
| September 30, 2016 | 96.91% |
| June 30, 2016 | 98.16% |
| March 31, 2016 | 93.79% |
| December 31, 2015 | 95.10% |
| September 30, 2015 | 95.60% |
| June 30, 2015 | 94.65% |
| March 31, 2015 | 94.93% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-140.3%
Minimum
Mar 2023
95.69%
Maximum
Dec 2022
-0.38%
Average
-5.18%
Median
Jun 2021
Gross Profit Margin (Quarterly) Benchmarks
| Biophytis SA | -- |
| DBV Technologies SA | -- |
| Genfit SA | -- |
| Edap TMS SA | 43.65% |
| Adaptimmune Therapeutics PLC | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -100.3% |
| Return on Assets | -39.35% |
| Return on Invested Capital | -79.08% |
| Profit Margin (Quarterly) | -15.15K% |
| Operating Margin (Quarterly) | -10.45K% |
| Return on Net Operating Assets | -51.43% |